In Europe, theoretical approaches to physical therapy and rehabilitation in multiple sclerosis
often appear significantly different. While there is general agreement that rehabilitation plays …

Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …

Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million
individuals globally. Recent approvals of ocrelizumab for primary progressive MS and …

Management of symptoms in multiple sclerosis (MS) has received little attention compared
with disease-modifying treatments. However, the effect of these symptoms on quality of life …

Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central
nervous system. Until recently, treatment has been largely confined to acute treatment of …

Multiple sclerosis is a chronic, progressive, and disabling disease of the central nervous
system, for which no cure exists. By the advent of immune modulating pharmacological …

Multiple sclerosis (MS) is an incurable disease, and despite current pharmacologic
treatment being effective in reducing relapse rates and lesion burden, there is little evidence …

Multiple sclerosis (MS) is the most common cause of physical disability in young adults. The
“Holy Grail” of MS research is to find a treatment that stops relapses, halts progression of the …

Background Multiple sclerosis (MS) is a major cause of chronic, neurological disability, with
a significant long‐term disability burden, often requiring comprehensive rehabilitation …

Introduction This randomised controlled trial (RCT) examines treadmill walking exercise
training effects on learning and memory performance, hippocampal volume, and …